Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists
about
Opioid-induced constipation: advances and clinical guidanceChronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunitiesDose-related antagonism of the emetic effect of morphine by methylnaltrexone in dogsTreatment of opioid-induced gut dysfunctionVgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas.Efficacy and Tolerability of Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: A Responder Analysis of 2 Randomized, Placebo-Controlled Trials.Spatiotemporal Mapping Techniques Show Clozapine Impairs Neurogenic and Myogenic Patterns of Activity in the Colon of the Rabbit in a Dose-Dependent MannerMethylnaltrexone: its pharmacological effects alone and effects on morphine in healthy volunteersMethylnaltrexone in the treatment of opioid-induced constipationOpioid receptors in the gastrointestinal tract.Antinociceptive effects of the novel opioid peptide BW443C compared with classical opiates; peripheral versus central actions.Preclinical studies of opioids and opioid antagonists on gastrointestinal function.Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients With Chronic Noncancer Pain: A Placebo Crossover Analysis.Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects.Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects.Emerging drugs for postoperative ileus.New approaches to the treatment of opioid-induced constipation.Emerging drugs for chronic constipation.Loss of μ opioid receptor signaling in nociceptors, but not microglia, abrogates morphine tolerance without disrupting analgesia.Methylnaltrexone bromide: research update of pharmacokinetics following parenteral administration.Opioid-induced constipation in advanced illness: safety and efficacy of methylnaltrexone bromide.Natural product and natural product derived drugs in clinical trials.Opioids and GI Motility-Friend or Foe?Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation.The peripheral narcotic antagonist N-allyl levallorphan-bromide (CM 32191) selectively prevents morphine antipropulsive action and buprenorphine in-vivo binding in the rat intestine.Methylnaltrexone and alvimopan: economic management of opioid-induced bowel dysfunction.Opioid involvement in hypertension induced by short-term isolation.Variations in demethylation of N-methylnaltrexone in mice, rats, dogs, and humans.WYE-120318, a ring contraction product of methylnaltrexone, and structure revision of coniothyrione.Antinociceptive Activity of Ent-Dihydrotucumanoic Acid Isolated from Gymnosperma glutinosum Spreng Less.Gut motility and transit changes in patients receiving long-term methadone maintenance.
P2860
Q26765571-883B489A-93BC-42D3-8237-339DD8E3A5ECQ28083547-C056AF18-E059-4826-B264-2CFD4C6F459DQ28264794-A3C03995-F620-49CE-B57A-CE4CC9F0D9C2Q28284578-43211217-DF17-4442-8FCD-6E9E9F390487Q33296232-43309208-F857-4909-AEA7-FA8C1A021B45Q33461577-8BF42FC5-4F1D-45E1-92F8-0A43AD4D4AE6Q33593376-D228F886-2600-4543-8221-4C56A7EC1B31Q34966995-A8EFDEC6-C6DE-44ED-BCC3-8D05980AB5C5Q35026245-EC44B302-EBAE-4BB0-9165-DB931204F18EQ35185222-D086D164-34AE-422A-8FE7-DA8904D9DE67Q35755177-BA2AEED5-F806-42FD-87A3-89C883107DA7Q35882832-44CB739F-05B8-46AF-97A0-C60A69E44692Q36384732-2BCF0AE4-6729-463C-8AD5-266438E37E75Q36458384-87A9D0AC-2DEC-4D41-8C42-838CEEA5AFCEQ36823204-A37E0BCC-7A77-4333-805B-35C8B291FB01Q36989931-D93F9F89-FF81-48A4-BAE2-947270BEE9ECQ37299608-C183CB74-C94C-4C80-85E4-772469A7333DQ37570550-604F53F9-FD61-4E2C-B7E9-21C15E56465EQ37629809-863B6E48-B01B-494E-8D53-762292B831D3Q37827493-F12F1F63-9D10-4E0A-B3E5-215D9172D274Q37916266-CEC0103F-0633-4050-8F1C-2BAB971F0C33Q38247457-4478DA65-C690-4DCC-84FE-2D2EDB7B5462Q38997203-12C8FF70-05D8-4F80-A10D-5ABAAC1F29C8Q39234260-714FA138-9D79-4BB0-A37C-2BF81E9A6901Q39554741-AFE2EA36-F7C0-4952-8154-95690431B729Q43266400-12C66171-013A-443C-BF44-A21CE1BF138BQ44330906-6E063F9F-E39A-4C15-B8B3-03A76D75F69DQ45201195-97E5F84D-AD75-423A-B4D8-8B236B0DBA14Q46238410-362000AA-27B6-4EEF-B4C7-85B324E48693Q47770129-D0078FA4-5FC7-4C56-A61B-406D9016677DQ51492773-F9B416EE-0585-48A8-BA89-BBC73BE5B314
P2860
Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists
description
1982 nî lūn-bûn
@nan
1982 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1982 թվականի մարտին հրատարակված գիտական հոդված
@hy
1982年の論文
@ja
1982年論文
@yue
1982年論文
@zh-hant
1982年論文
@zh-hk
1982年論文
@zh-mo
1982年論文
@zh-tw
1982年论文
@wuu
name
Antagonism of gut, but not cen ...... uaternary narcotic antagonists
@ast
Antagonism of gut, but not cen ...... uaternary narcotic antagonists
@en
Antagonism of gut, but not cen ...... uaternary narcotic antagonists
@nl
type
label
Antagonism of gut, but not cen ...... uaternary narcotic antagonists
@ast
Antagonism of gut, but not cen ...... uaternary narcotic antagonists
@en
Antagonism of gut, but not cen ...... uaternary narcotic antagonists
@nl
prefLabel
Antagonism of gut, but not cen ...... uaternary narcotic antagonists
@ast
Antagonism of gut, but not cen ...... uaternary narcotic antagonists
@en
Antagonism of gut, but not cen ...... uaternary narcotic antagonists
@nl
P2093
P1476
Antagonism of gut, but not cen ...... uaternary narcotic antagonists
@en
P2093
P304
P356
10.1016/0014-2999(82)90026-7
P407
P577
1982-03-12T00:00:00Z